Could a common diabetes drug help fight prostate cancer?

NCT ID NCT07310433

Not yet recruiting Disease control Sponsor: Yung NA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding dapagliflozin, a diabetes medication, to standard hormone therapy improves outcomes for men with metastatic castrate-resistant prostate cancer. About 60 participants will be randomly assigned to receive either the combination or standard care alone. The study aims to see if the combination delays cancer progression and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a diabetes drug) combined with standard hormone therapy
What this could lead to: If successful, this could point toward a new combination treatment that improves tumor control for men with advanced prostate cancer.
What could go wrong: This is a small, early-phase trial (60 people) and the drug is being repurposed, so results may not be conclusive or generalizable. Side effects from the combination are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Huashan Hospital

Shanghai, China
Ruijin Hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.